Related Experiment Video
Updated: Jun 11, 2026
02:28
Measuring Psoriasis Severity at Home
Published on: March 1, 2024
Difference between patient-reported side effects of ciclesonide versus fluticasone propionate
Thys van der Molen1, Juliet M Foster, Manfred Caeser
1Department of General Practice, University Medical Center Groningen, University of Groningen, Hanzeplein 1, Groningen, The Netherlands.
Respiratory Medicine
|June 30, 2010
Summary
Patients with moderate-to-severe asthma reported fewer side effects with ciclesonide compared to fluticasone propionate. The Inhaled Corticosteroid Questionnaire (ICQ) assessed patient-perceived treatment side effects.
Area of Science:
- Pulmonology
- Pharmacology
- Clinical Trials
Background:
- Patient-reported outcomes offer valuable insights into asthma management.
- The Inhaled Corticosteroid Questionnaire (ICQ) is a validated tool for assessing treatment side effects.
- Understanding patient-perceived side effects is crucial for optimizing asthma therapy.
Purpose of the Study:
- To compare patient-reported side effects between two inhaled corticosteroids: ciclesonide and fluticasone propionate.
- To evaluate differences in local and systemic side effect profiles.
- To assess patient perception of treatment tolerability in moderate-to-severe asthma.
Main Methods:
- Randomized controlled trials comparing ciclesonide and fluticasone propionate in adult patients with moderate-to-severe asthma.
- Three studies were conducted with varying dosages and administration frequencies of the inhaled corticosteroids.
- The 15-domain Inhaled Corticosteroid Questionnaire (ICQ) was used to rate side effects on a 7-point Likert scale.
Main Results:
- Ciclesonide generally maintained similar side effect scores, while fluticasone propionate showed statistically significant worsening.
- Ciclesonide demonstrated significant improvements in total side effect scores and several individual domains compared to fluticasone propionate in two of the three studies.
- Oropharyngeal itching was a statistically significant side effect improved by ciclesonide in one study.
Conclusions:
- Patient-perceived side effects vary significantly between ciclesonide and fluticasone propionate.
- Ciclesonide is associated with less intense patient-reported side effects compared to fluticasone propionate in moderate-to-severe asthma.
- These findings highlight the importance of considering patient-reported outcomes in inhaled corticosteroid selection.
Related Concept Videos
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:24Asthma-III: Symptoms and Complications
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
01:13Asthma III: Clinical Manifestations
Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...